Eu­ro­pean reg­u­la­tors ex­pand use of Ab­b­Vie's two-month hep C reg­i­men

The land­scape of he­pati­tis C — once a dev­as­tat­ing liv­er-dam­ag­ing dis­ease — has changed dra­mat­i­cal­ly since 2014, when the first raft of new ther­a­pies ush­ered in an era that has cul­mi­nat­ed in po­ten­tial cure rates of more than 90% to­day, re­gard­less of the pa­tient’s geno­type. The first of these rev­o­lu­tion­ary but pricey drugs was So­val­di — its mak­er Gilead de­buted the three-month reg­i­men at an eye-pop­ping $1,000 a pill.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER